QUANTUM GENOMICS: Progress report – 08/12/2022 at 18:00


Waypoint

Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs that act directly on the brain, provides an update after the announcement on October 28, 2022 of the negative results of its phase study III FRESH.

Cash position

The company’s cash position amounts to €10.6 million as of December 7, 2022. As the company has decided to also stop its second phase III REFRESH study, as well as all related developments, discussions are continuing. with the various stakeholders to settle and close the activities in progress.

Ongoing discussions with Biotech / Medtech companies

The company has initiated discussions with Biotech and Medtech companies, listed and unlisted, and is studying all the opportunities and methods of possible mergers to build a new business project.

In connection with these interactions, the company discusses with its historical investors and new investors.

BAPAIs platform

At the same time, the company is investigating any possible repositioning of firibastat in other indications apart from resistant hypertension and heart failure.

Next communication

The company expects a new milestone no later than February 2023.

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the mechanism of inhibition of brain Aminopeptidase A (Brain Aminopeptidase A Inhibition or BAPAI). The only company in the world to pursue this innovative approach directly targeting the brain, it relies on more than twenty years of research from the University of Paris-Descartes and the INSERM/CNRS laboratory directed by Dr. Catherine Llorens-Cortès at France secondary school.

Based in Paris and New York, the company is listed on the Euronext Growth market in Paris (FR0011648971 – ALQGC) and registered on the American market OTCQX (symbol: QNNTF).

More information on www.quantum-genomics.com, our Twitter and Linkedin accounts

contacts

Quantum Genomics

[email protected]

Communication building (EUROPE)

Financial communication and media

[email protected]

LifeSci (US)

Mike Tattory

Media communications

+1 (646) 751-4362 – [email protected]


This post has the “? Actusnews SECURITY MASTER” service.


– SECURITY MASTER Key:

lW1rYZackmaVl2meZ5Vub2OWmZeTxGeZl5KZmWNrZZyUm2tpm5dnbJ2dZnBommxu

– To check this key:

https://www.security-master-key.com.



Regulated information:


Inside information:

– Other press releases


Full and original press release in PDF format:

https://www.actusnews.com/news/77578-cp-8-decembre-2022.pdf

© Copyright Actusnews Wire

Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com



Source link -86